Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 478

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 478
---
 31, 2023 and 2022                                                                             |     | F-7  |
| Notes to Consolidated Financial Statements                                                    |     | F-9  |
| Unaudited Interim Condensed Financial Statements for the Nine Months Ended September 30, 2024 
 and 2023                                                                                      |     |      |
| Condensed Consolidated Balance Sheets – September                                             
 30, 2024 and December 31, 2023 (Unaudited)                                                    |     | F-32 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss –                      
 Three and Nine Months Ended September 30, 2024 and 2023 (Unaudited)                           |     | F-33 |
| Condensed Consolidated Statements of Stockholders’ Equity – Three and                         
 Nine Months Ended September 30, 2024 and 2023 (Unaudited)                                     |     | F-34 |
| Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30,             
 2024 and 2023 (Unaudited)                                                                     |     | F-36 |
| Notes to Condensed Consolidated Financial Statements                                          
 (Unaudited)                                                                                   |     | F-37 |

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors

Aadi Bioscience,
Inc.

Pacific Palisades, California

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Aadi Bioscience, Inc. (the “Company”) as
of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively, referred to as the
“consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its
operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (“PC